Sujentec Rises 5.1% Amid Uptrend in COVID-19 (Diagnostics/Treatment/Vaccine Development) Theme

On the 18th, the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme rose by 3.09% compared to the previous day, showing strength, while SuzenTec, a related stock attracting attention, surged by 5.1% compared to the previous day. SuzenTec is known as a manufacturer and seller of medical devices and diagnostic reagents.

[Graph] Major stock price changes in the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme



According to provisional data compiled at 11:06, foreign investors are net buying 1,000 shares of SuzenTec.

[Table] Net trading volume of foreigners and institutions (unit: 10,000 shares)



According to the analysis by Thinkpool RoboAlgorithm RASSI, SuzenTec’s quant financial score is 9.92 points, with higher growth and stability scores than the average of other stocks related to COVID-19 (diagnosis/treatment/vaccine development, etc.), but its quant financial ranking was only 34th out of 56 stocks. On the other hand, United Pharm ranked first in quant financial ranking with higher growth, stability, and profitability scores compared to other stocks.

[Table] Top financial scores within the theme


※ The quant financial score is the result of RoboAlgorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.